US Pharma MarketingThe post ALZAI reports validation of Alzheimer’s risk identification models appeared first on Medical Device Network.
ALZAI reports validation of Alzheimer’s risk identification models
ALZAI Health has reported the validation of its AI-driven Alzheimer’s disease risk identification models using data from over 1.1 million patients in the US. The validation used a HealthVerity dataset with 38 million lab test results and over three million diagnostic records. Alzai Health’s technology is intended for Alzheimer’s disease risk identification. Credit: digicomphoto / Shutterstock.com. ALZAI Health has reported the validation of its AI-driven Alzheimer’s disease risk identification models using data from more than 1.1 million patients in the US. The company reported that its risk-stratification models achieved performance comparable to earlier validations that used Israeli healthcare data. Combine…
ALZAI Health has reported the validation of its AI-driven Alzheimer’s disease risk identification models using data from over 1.1 million patients in the US.
Source: Medical Device Network